Radiotherapeutic Management and Prognostic Factors for Patients with Bone Metastases of Postoperative Breast Cancer

CAI Gang,CHEN Jia-yi,ZHU Ji,YU Xiao-li,ZHANG Zhen,GUO Xiao-mao,HU Chao-su

DOI: https://doi.org/10.3969/j.issn.1007-3639.2008.03.009

2008-01-01

Abstract:Background and purpose:Radiotherapy is used commonly to provide pain relief for bone metastases of breast cancer.Our aim was to evaluate the treatment outcome of palliative radiotherapy and the prognostic factors for survival in patients with bone metastasis of breast cancer. Methods :One hundred and eighty-six patients with bone metastases of breast cancer were treated with palliative radiotherapy between Jan.2000 and Aug.2005 were retrospectively analyzed.323 sites received irradiation.Radiation therapy was delivered using 60 Co or 6 MV X ray,with either a single beam or anterior-posterior beams.The total dose ranged from 20-60 Gy,with a median dose of 30 Gy. Results :Thoracic and lumbar vertebra,ribs and ilium were the most common metastatic sites.The median survival time was 34 months and 37.5 months in the entire cohort and in 112 cases with bone metastasis as first events respectively.Overall clinical response(complete and partial symptom relief) with radiation therapy was achieved in 90.8% of the patients with complete relief in 42.1% of all cases.The onset of symptom relief occurred within 4 weeks after the end of radiotherapy in 75.3% of the patients.The median duration of symptom relief was 23 month,which was over 22 months in those received a BED of ≥39 Gy,and 8 months in the sub-group of ≤30 Gy or less.Hormone receptors status,number of positive nodes,viscera metastasis,and solitary vs multiple skeletal metastases were independent prognostic factors for survival by multivariate analyses. Conclusions :Radiotherapy is an effective palliative approach for patients with bone metastases of breast cancer.Majority of the patients benefited from clinical response and the median duration of symptom relief lasted about 2/3 of the remaining survival time.Receptors status,number of positive nodes,viscera involvement,and solitary vs multiple skeletal metastases were independent prognostic factors for survival.